ENO1 is frequently overexpressed and is consistently linked to poor prognosis, advanced stage, and aggressive tumor features across multiple malignancies, including breast, lung, bladder, prostate, gastric, colorectal, pancreatic, and thyroid cancers [75,76,77,78]. This evidence concerns the gene ENO1 and thyroid cancer.